Elevated serum levels of interleukin-18 in patients with overt diabetic nephropathy: Effects of miglitol

Clinical and Experimental Nephrology

Volumn 15, Issue 1, 2011, Pages 58-63

  Uzu, Takashi ^a   Yokoyama, Hiroki ^b   Itoh, Hirofumi ^b   Koya, Daisuke ^c   Nakagawa, Atsushi ^c   Nishizawa, Makoto ^c   Maegawa, Hiroshi ^a   Yokomaku, Yukiyo ^a   Araki, Shin Ichi ^a   Abiko, Atsuko ^d   Haneda, Masakazu ^d  

^a SHIGA UNIVERSITY OF MEDICAL SCIENCE   (Japan)

^b Jiyugaoka Medical Clinic   (Japan)

^c KANAZAWA MEDICAL UNIVERSITY   (Japan)

^d ASAHIKAWA MEDICAL COLLEGE   (Japan)

Author keywords

Glucosidase inhibitors; Diabetic nephropathy; Hyperglycemia; Postprandial; Proinflammatory cytokine

Indexed keywords

GLUCOSE; GLYCOSYLATED HEMOGLOBIN; INSULIN; INTERLEUKIN 18; MIGLITOL;

ABDOMINAL DISCOMFORT; AGED; ARTICLE; BLOOD PRESSURE; BODY WEIGHT; CLINICAL ARTICLE; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DIABETIC NEPHROPATHY; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG FATALITY; DRUG MECHANISM; DRUG SAFETY; DRUG TOLERANCE; DRUG WITHDRAWAL; FEMALE; GLOMERULUS FILTRATION RATE; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYPERGLYCEMIA; INSULIN BLOOD LEVEL; JAPANESE; KIDNEY FUNCTION; KIDNEY FUNCTION TEST; LIVER FUNCTION; LIVER FUNCTION TEST; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PROTEIN BLOOD LEVEL; PROTEINURIA; SIDE EFFECT;

1-DEOXYNOJIRIMYCIN; DIABETES MELLITUS, TYPE 2; DIABETIC NEPHROPATHIES; ENZYME INHIBITORS; HUMANS; HYPERGLYCEMIA; HYPOGLYCEMIC AGENTS; INTERLEUKIN-18; POSTPRANDIAL PERIOD;

EID: 79952187280     PISSN: 13421751     EISSN: 14377799     Source Type: Journal    
DOI: 10.1007/s10157-010-0343-7     Document Type: Article

References (35)

1. M Laakso 1999 Hyperglycemia and cardiovascular disease in type 2 diabetes Diabetes 48 937 942 1:CAS:528:DyaK1MXjtFSgsLk%3D 10.2337/diabetes.48.5.937 10331395 (Pubitemid 29226337)
2. JA Beckman MA Creager P Libby 2002 Diabetes and atherosclerosis: epidemiology, pathophysiology and management JAMA 2002 2570 2581 10.1001/jama.287.19.2570 (Pubitemid 34517204)
3. AI Adler RJ Stevens SE Manley RW Bilous CA Cull RR Holman 2003 Development and progression of nephropathy in type 2 diabetes: the United Kingdom Prospective Diabetes Study (UKPDS 64) Kidney Int 63 225 232 10.1046/j.1523-1755.2003.00712.x 12472787 (Pubitemid 35463925)
4. R Ross 1999 Atherosclerosis: an inflammatory disease N Engl J Med 340 115 126 1:STN:280:DyaK1M%2FptFSqtQ%3D%3D 10.1056/NEJM199901143400207 9887164 (Pubitemid 29054847)
5. AJ Puren G Fantuzzi Y Gu MS Su CA Dinarello 1998 Interleukin-18 (IFNgamma-inducing factor) induces IL-8 and IL-1beta via TNFalpha production from non-CD14+ human blood mononuclear cells J Clin Invest 101 711 721 1:CAS:528:DyaK1cXosVamtw%3D%3D 10.1172/JCI1379 9449707 (Pubitemid 28084257)
6. A Zirlik SM Abdullah N Gerdes L MacFarlane U Schönbeck A Khera, et al. 2007 Interleukin-18, the metabolic syndrome, and subclinical atherosclerosis: results from the Dallas Heart Study Arterioscler Thromb Vasc Biol 27 2043 2049 1:CAS:528:DC%2BD2sXpt1Cis7g%3D 10.1161/ATVBAHA.107.149484 17626902 (Pubitemid 47312316)
7. BM Everett S Bansal N Rifai JEPMR Buring 2009 Interleukin-18 and the risk of future cardiovascular disease among initially healthy women Atherosclerosis 202 282 288 1:CAS:528:DC%2BD1cXhsFajsbzJ 10.1016/j.atherosclerosis.2008.04.015 18514203
8. P Skopiński E Rogala B Duda-Król A Lipińska E Sommer J Chorostowska-Wynimko 2005 Increased interleukin-18 content and angiogenic activity of sera from diabetic (Type 2) patients with background retinopathy J Diabetes Complicat 19 335 338 10.1016/j.jdiacomp.2005.02.008 16260350 (Pubitemid 41563016)
9. A Nakamura K Shikata M Hiramatsu T Nakatou T Kitamura J Wada, et al. 2005 Serum interleukin-18 levels are associated with nephropathy and atherosclerosis in Japanese patients with type 2 diabetes Diabetes Care 28 2890 2895 1:CAS:528:DC%2BD28XhsFE%3D 10.2337/diacare.28.12.2890 16306550 (Pubitemid 43942920)
10. S Araki M Haneda D Koya T Sugimoto K Isshiki M Chin-Kanasaki, et al. 2007 Predictive impact of elevated serum level of IL-18 for early renal dysfunction in type 2 diabetes: an observational follow-up study Diabetologia 50 867 873 1:CAS:528:DC%2BD2sXitlOntrs%3D 10.1007/s00125-006-0586-8 17225121 (Pubitemid 46355823)
11. DM Nathan JB Buse MB Davidson RJ Heine RR Holman R Sherwin, et al. 2006 Management of hyperglycemia in Type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy. A consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes Diabetes Care 29 1963 1972 10.2337/dc06-9912 16873813 (Pubitemid 44156663)
12. A Ceriello S Colagiuri 2008 International Diabetes Federation guideline for management of postmeal glucose: a review of recommendations Diabet Med 25 1151 1156 1:CAS:528:DC%2BD1cXhsVSiurzL 10.1111/j.1464-5491.2008.02565.x 19046192
13. CP Fischer LB Perstrup A Berntsen P Eskildsen BK Pedersen 2005 Elevated plasma interleukin-18 is a marker of insulin-resistance in type 2 diabetic and non-diabetic humans Clin Immunol 117 152 160 1:CAS:528:DC%2BD2MXhtVyms7jI 10.1016/j.clim.2005.07.008 16112617 (Pubitemid 41407725)
14. C Herder S Schneitler W Rathmann B Haastert H Schneitler H Winkler, et al. 2007 Low-grade inflammation, obesity, and insulin resistance in adolescents J Clin Endocrinol Metab 92 4569 4574 1:CAS:528:DC%2BD1cXmslWht7g%3D 10.1210/jc.2007-0955 17911172 (Pubitemid 350223428)
15. AE Altinova I Yetkin E Akbay N Bukan M Arslan 2008 Serum IL-18 levels in patients with type 1 diabetes: relations to metabolic control and microvascular complications Cytokine 42 217 221 1:CAS:528:DC%2BD1cXlslyntLY%3D 10.1016/j.cyto.2008.02.006 18359638
16. HJ Ahr M Boberg E Brendel HP Krause W Steinke 1997 Pharmacokinetics of miglitol Absorption, distribution, metabolism, and excretion following administration to rats, dogs, and man Arzneimittelforschung 47 734 745 1:CAS:528:DyaK2sXktlGnsLc%3D 9239452
17. GO Guerrant CW Moss 1984 Determination of monosaccharides as aldononitrile, o-methyloxime, alditol, and cyclitol acetate derivatives by gas chromatography Anal Chem 56 633 638 1:CAS:528:DyaL2cXhtFOgs7c%3D 10.1021/ac00268a010 (Pubitemid 14568630)
18. S Matsuo E Imai M Horio Y Yasuda K Tomita K Nitta, et al. 2009 Revised equations for estimated GFR from serum creatinine in Japan Am J Kidney Dis 53 982 992 1:CAS:528:DC%2BD1MXnslKku7c%3D 10.1053/j.ajkd.2008.12.034 19339088
19. JR Sowers M Epstein ED Frohlich 2001 Diabetes, hypertension, and cardiovascular disease: an update Hypertension 37 1053 1059 1:CAS:528: DC%2BD3MXjtFejt7g%3D 11304502 (Pubitemid 32304003)
20. CG Solomon 2003 Reducing cardiovascular risk in type 2 diabetes N Engl J Med 348 457 459 10.1056/NEJMe020172 12556548 (Pubitemid 36159365)
21. Z Mallat A Corbaz A Scoazec S Besnard G Lesèche Y Chvatchko, et al. 2001 Expression of interleukin-18 in human atherosclerotic plaques and relation to plaque instability Circulation 104 1598 1603 1:CAS:528: DC%2BD3MXotVehtrc%3D 10.1161/hc3901.096721 11581135 (Pubitemid 32947520)
22. P Welsh M Woodward A Rumley G Lowe 2009 Associations of circulating TNFalpha and IL-18 with myocardial infarction and cardiovascular risk markers: the Glasgow Myocardial Infarction Study Cytokine 47 143 147 1:CAS:528: DC%2BD1MXptVGltrg%3D 10.1016/j.cyto.2009.06.002 19581111
23. KE Wellen GS Hotamisligil 2005 Inflammation, stress, and diabetes J Clin Invest 115 1111 1119 1:CAS:528:DC%2BD2MXktFSksbY%3D 15864338 (Pubitemid 40629025)
24. JG Dickhout JC Krepinsky 2009 Endoplasmic reticulum stress and renal disease Antioxid Redox Signal 11 2341 2352 1:CAS:528:DC%2BD1MXpvFaru7c%3D 10.1089/ars.2009.2705 19508129
25. M Brownlee 2001 Biochemistry and molecular cell biology of diabetic complications Nature 414 813 820 1:CAS:528:DC%2BD38Xhtlyltg%3D%3D 10.1038/414813a 11742414 (Pubitemid 34000785)
26. F Vidal-Vanaclocha G Fantuzzi L Mendoza AM Fuentes MJ Anasagasti J Martín, et al. 2000 L-18 regulates IL-1β-dependent hepatic melanoma metastasis via vascular cell adhesion molecule-1 PNAS 97 734 739 1:CAS:528:DC%2BD3cXot1agsQ%3D%3D 10.1073/pnas.97.2.734 10639148 (Pubitemid 30070378)
27. K Berneis M Rizzo J Evans GB Rini GA Spinas JH Goedecke 2010 Interleukin-18 levels are associated with low-density lipoproteins size Eur J Clin Invest 40 54 55 1:CAS:528:DC%2BC3cXht1Kitrk%3D 10.1111/j.1365-2362.2009. 02228.x 19968699
28. T Porazko J Kúzniar M Kusztal TJ Kúzniar W Weyde M Kuriata-Kordek, et al. 2009 IL-18 is involved in vascular injury in end-stage renal disease patients Nephrol Dial Transplant 24 589 596 1:CAS:528: DC%2BD1MXotlGhuw%3D%3D 10.1093/ndt/gfn486 18775894
29. UK Prospective Diabetes Study Group 1999 Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38 BMJ 12 703 713
30. American Diabetes Association 2009 Standards of medical care in diabetes - 2009 Diabetes Care 2009 Suppl 1 S13 S61 10.2337/dc09-S013
31. G Charpentier JP Riveline M Varroud-Vial 2000 Management of drugs affecting blood glucose in diabetic patients with renal failure Diabetes Metab 26 Suppl4 73 85 1:CAS:528:DC%2BD3cXmslSksLo%3D 10922977 (Pubitemid 30618360)
32. DJ Baer JT Judd BA Clevidence RP Tracy 2004 Dietary fatty acids affect plasma markers of inflammation in healthy men fed controlled diets: a randomized crossover study Am J Clin Nutr 79 969 973 1:CAS:528:DC%2BD2cXksVyqtbw%3D 15159225 (Pubitemid 41095947)
33. H Ghanim S Abuaysheh CL Sia K Korzeniewski A Chaudhuri JM Fernandez-Real 2009 Increase in plasma endotoxin concentrations and the expression of Toll-like receptors and suppressor of cytokine signaling-3 in mononuclear cells after a high-fat, high-carbohydrate meal: implications for insulin resistance Diabetes Care 32 2281 2287 1:CAS:528:DC%2BC3cXktlajsQ%3D%3D 10.2337/dc09-0979 19755625
34. M Arakawa C Ebato T Mita Y Fujitani T Shimizu H Watada, et al. 2008 Miglitol suppresses the postprandial increase in interleukin 6 and enhances active glucagon-like peptide 1 secretion in viscerally obese subjects Metabolism 57 1299 1306 1:CAS:528:DC%2BD1cXhtVWit7nL 10.1016/j.metabol.2008.04.027 18702958
35. R Assaloni R Da Ros L Quagliaro L Piconi A Maier G Zuodar, et al. 2005 Effects of S21403 (mitiglinide) on postprandial generation of oxidative stress and inflammation in type 2 diabetic patients Diabetologia 48 1919 1924 1:CAS:528:DC%2BD2MXhtVSqt7bM 10.1007/s00125-005-1849-5 16007412 (Pubitemid 41317849)